Phototherapy Machine for Home: Benefits & Use Cases

You have probably tried the creams. Maybe they helped for a while, or maybe they never quite did enough. Perhaps your dermatologist has suggested light therapy as a next step. Perhaps you have already been attending clinic sessions and are now wondering whether you can continue that treatment at home. Or perhaps you have been living with psoriasis, eczema, or vitiligo for years and are still looking for something that genuinely works.
Wherever you are in that journey, this article is for you. It covers what a phototherapy machine is, what the clinical evidence says about home use, and how this treatment could help you manage a condition that, on many days, asks a great deal of you.

What Is a Phototherapy Machine and How Does It Work?

Phototherapy is not a new idea. Dermatologists have been using ultraviolet light to treat chronic skin conditions since the 1980s, and the clinical evidence behind it has only grown stronger over the decades. A phototherapy machine — also referred to as a phototherapy unit or UVB lamp — delivers controlled doses of ultraviolet light directly to affected skin. The purpose is therapeutic: to interrupt the immune and cellular processes that drive conditions such as psoriasis, eczema, and vitiligo.
The wavelength that changed dermatology
Not all ultraviolet light is equal. Broadband UVB, UVA, and the UV found in ordinary sunlight contain a wide spectrum of wavelengths — many of which carry risk without adding therapeutic benefit. What transformed phototherapy practice was the isolation of a very specific wavelength: 311 nanometres. Narrowband UVB (NB-UVB) at 311 nm delivers the clinically active portion of the UV spectrum whilst minimising exposure to wavelengths associated with unnecessary skin damage. It is now the most widely recommended form of phototherapy in clinical guidelines across Europe and the UK, including those of the British Association of Dermatologists and British Photodermatology Group (BAD/BPG).
What happens at the cellular level
When 311 nm UVB light reaches the skin, it triggers a cascade of biological responses that directly target the mechanisms underlying several chronic inflammatory skin conditions. In psoriasis, an overactive immune response drives skin cells to multiply far too rapidly — producing the characteristic plaques. NB-UVB suppresses the T-cell activity driving this process and reduces the production of pro-inflammatory signals. In vitiligo, the same wavelength stimulates melanocyte activity and migration, supporting repigmentation of depigmented patches. In eczema, it reduces inflammatory immune activity in the skin, calming the persistent itch-scratch cycle that makes the condition so exhausting to live with.
This mechanism also explains something many people with psoriasis have noticed: that their skin often improves in summer. Natural sunlight contains some NB-UVB — but in variable, uncontrolled amounts that shift with season, latitude, and weather. A medical phototherapy unit delivers the same therapeutic wavelength in a measured, repeatable dose every single time.
What the evidence actually says about home light therapy
For most of its history, phototherapy meant clinic visits — typically three sessions per week, sustained over weeks or months. The treatment works well; the logistics are what make it difficult to complete. Waiting lists, travel, time away from work, and the sheer repetition of frequent appointments are genuine barriers. And completing a full course matters — because consistency is what drives results.
This is why the British Association of Dermatologists and British Photodermatology Group 2022 guidelines formally endorse home NB-UVB as a valid treatment setting, provided a medical-grade device with correct dosing is used. They specifically recommend home phototherapy to improve access where waiting times or geographical barriers exist.
The most significant clinical evidence to date comes from the LITE Randomised Clinical Trial, published in JAMA Dermatology in 2024. Conducted across 42 clinical sites with 783 patients, the trial confirmed that home-based NB-UVB phototherapy is non-inferior to office-based treatment for psoriasis across all skin types — meaning it produces equivalent clinical results. But the findings went further than equivalence. Home-based patients showed significantly better treatment adherence — 51.4% compared with 15.9% in the clinic group. The lead researcher, Professor Joel Gelfand of the University of Pennsylvania, directly attributed better patient outcomes to that adherence advantage: when treatment fits into a person's daily life rather than around it, they are far more likely to complete it. On the basis of this evidence, the LITE investigators concluded that home phototherapy should be considered a first-line treatment option for plaque and guttate psoriasis when a dermatologist considers it medically appropriate.

"Patients achieve excellent outcomes both at home and in the office — but patients treated at home had better outcomes, likely related to much better adherence to treatment." — Prof. Joel Gelfand, Principal Investigator, LITE Trial, JAMA Dermatology 2024

Who Can Benefit from At-Home UVB Phototherapy?

NB-UVB phototherapy has documented clinical efficacy across a wide range of skin conditions. The BAD/BPG 2022 guidelines cover 38 conditions for which phototherapy recommendations have been developed. For the purposes of home phototherapy, three conditions represent the clearest and most established use cases.
Psoriasis
Psoriasis is the condition with the strongest and most extensive evidence base for NB-UVB phototherapy. According to the BAD/BPG 2022 guidelines, NB-UVB should be offered to people with psoriasis — typically as a second-line option when topical treatments are insufficient, not tolerated, or not suitable for long-term use. It can also be a first-line choice for patients who prefer to avoid steroids or other medications, or for those who are already experiencing side effects from their current treatment. A typical course involves three sessions per week, with meaningful improvement generally developing over 20 to 30 sessions. Results require consistency and time — but the evidence is clear that when a course is completed properly, it works.
Eczema (atopic dermatitis)
For eczema, NB-UVB is an established next-line treatment when topical therapies alone are not achieving adequate control. The BAD/BPG guidelines recommend it specifically for this purpose, noting that any acute flare should be managed before starting a course of phototherapy. It is also compatible with topical treatments — the two approaches can be used alongside each other under medical guidance.
Vitiligo
Vitiligo has a particularly strong relationship with NB-UVB. The BAD/BPG 2022 guidelines position NB-UVB as first-line phototherapy for people with vitiligo who have had an inadequate response to topical therapy, or who have extensive or progressive disease. Treatment courses for vitiligo are typically longer than for psoriasis or eczema — repigmentation can take several months to a year — but the evidence for its effectiveness is well established.
Home-based handheld phototherapy is specifically named in the guidelines as a suitable delivery method for vitiligo treatment.
A note on results and individual variation
It is worth being clear about what phototherapy does and does not do. It manages and controls these conditions — it does not cure them. Symptoms can return after a course of treatment ends, and some patients will need repeated courses over time. Remission is achievable and can be sustained, particularly when supported by regular use of emollients, appropriate skin care, and where relevant, lifestyle factors. For some patients, a dermatologist may recommend a maintenance therapy schedule to help prolong remission between full courses.
Results vary between individuals, and the degree of improvement depends on condition severity, skin type, consistency of treatment, and how well the correct protocol is followed.
Skin type matters in particular. Earlier concerns that phototherapy was less well studied in darker skin tones have now been directly addressed: the LITE Trial specifically enrolled patients across all skin types and confirmed equivalent outcomes regardless of skin tone.
Who is not suitable
Phototherapy is not appropriate for everyone. It is contraindicated in people with photosensitive conditions such as lupus erythematosus or xeroderma pigmentosum, and in those with a history of melanoma or multiple non-melanoma skin cancers. Certain immunosuppressant medications — including ciclosporin and azathioprine — are also contraindications due to the increased risk of photocarcinogenesis. Some other medications can increase photosensitivity and require careful assessment before treatment begins.
This is why a consultation with a dermatologist before starting any course of phototherapy — at home or in a clinic — is not optional. It is the foundation of safe treatment.

Key Benefits of Using a Home Phototherapy Machine

The clinical case for NB-UVB phototherapy is well established. But for many patients, the practical barriers to accessing it in a clinic setting are just as significant as the condition itself. Home phototherapy exists precisely to remove those barriers — and the benefits go beyond simple convenience.
Treatment on your terms
Clinic phototherapy typically requires three visits per week, sustained over weeks or months. For most people, that means time off work, travel costs, childcare arrangements, and the mental load of fitting a demanding schedule around an already demanding condition. Phototherapy centres are also concentrated predominantly in larger cities — for people living in smaller towns or rural areas, the nearest clinic may simply not be a realistic option, regardless of how motivated they are to complete treatment. Many patients simply cannot sustain it — and when treatment is interrupted, results suffer.
At home, the same treatment happens in minutes, in your own space, at a time that suits you. The LITE Trial found that home-based patients were more than three times as likely to adhere to their prescribed treatment schedule compared with those attending a clinic — 51.4% versus 15.9%. As the trial's lead researcher noted, this adherence advantage translated directly into better patient outcomes. Consistency is not a minor detail in phototherapy. It is the difference between a course that works and one that does not.
No waiting lists
In the UK, NHS dermatology waiting times are a serious and documented problem. A review of NHS hospitals across England found an average wait of 43 weeks just to receive a dermatology appointment and commence treatment — well beyond the 18-week target set by the NHS Constitution. In some cases, patients have waited several years. For a condition that is progressive and deeply affects quality of life, that wait is not a neutral inconvenience — it is lost time during which symptoms continue to worsen. A home phototherapy unit means treatment can begin when it is clinically appropriate, not when a slot eventually becomes available.
Treat early, before symptoms escalate
One advantage that is easy to overlook: when you have a phototherapy unit at home, you can begin treatment as soon as symptoms start to flare — without waiting for a clinic appointment, a referral, or an available slot. Research published in Dermatological Reviews notes that home-based phototherapy can be initiated early in disease progression — at a stage when hospital or clinic phototherapy may not yet be available to a patient because the affected area has not reached the threshold required for referral. Early treatment improves outcomes. Having the means to act at the right moment matters.
Steroid-free and non-invasive
For patients who are seeking to reduce or avoid dependence on topical steroids, or who have experienced side effects from other treatments, phototherapy offers a non-pharmacological alternative with a well-established safety profile. Research published in PLOS ONE found that NB-UVB treatment led to a significant reduction in the use of steroid creams in psoriasis patients in clinical practice. It can also be used alongside existing treatments — complementing topicals or systemics rather than replacing them entirely.
Mental health and quality of life
Chronic skin conditions carry a burden that extends well beyond the skin. Persistent symptoms, visible flares, and the unpredictability of a condition that cannot be fully controlled take a real toll on mental wellbeing. The same Dermatological Reviews research identifies a reduction in anxiety symptoms as a documented benefit of home-based phototherapy — a finding that reflects what patients already know from experience: that regaining some control over your condition changes how you feel about it.
Privacy and dignity
Skin conditions affect more than the skin. Many people find clinic visits — undressing, being examined, being seen — difficult. Treating at home means managing your condition entirely in private, without that additional layer of exposure.
Long-term value
The cost picture for phototherapy varies depending on where you are and how your healthcare system works. In many European countries, clinic-based phototherapy is covered or partially reimbursed through public health insurance — so the financial comparison between home and clinic is not always straightforward. But long-term value is not only about money. The most important factor is whether you actually complete the treatment. A course of phototherapy that is interrupted, delayed, or abandoned produces no results — and the evidence shows that most patients who struggle to complete clinic-based treatment do so not because the therapy fails them, but because the logistics do. Travel, waiting times, rigid scheduling, and the sheer repetition of three visits per week over months are what cause people to quit. When treatment is at home, those barriers disappear — and completion becomes realistic. That is the real value of a home phototherapy device: not just what it costs, but what it makes possible. What a home device also changes, regardless of reimbursement, is the full picture of what treatment actually costs you in time and indirect burden. Research published in Photodermatology, Photoimmunology & Photomedicine calculated that the indirect costs of clinic-based phototherapy are substantial — and that widening access to home treatment generates significant savings when those factors are taken into account. For patients managing a lifelong condition, that calculation compounds over time.

A home phototherapy unit is not a shortcut. It is the same clinically validated treatment — with the freedom to actually complete it.

Is At-Home UVB Phototherapy Safe?

NB-UVB phototherapy has one of the most thoroughly studied safety profiles of any treatment used in dermatology. It has been in clinical use for decades, across tens of thousands of patients, and the evidence base is substantial. That said, like any medical treatment, it carries risks that are worth understanding clearly — because informed patients make better decisions, and because responsible use is what produces good outcomes.
The question people ask most: does UV light cause skin cancer?
It is a fair question, and it deserves a direct answer. The concern arises from the well-established link between UV radiation and skin cancer — but the research on NB-UVB phototherapy specifically tells a more reassuring story. A large analysis of 3,867 patients treated with NB-UVB phototherapy in a clinic setting, with follow-up of up to 22 years, found no established association between NB-UVB phototherapy and skin cancers. A retrospective cohort study of 3,506 patients treated with NB-UVB found no increased risk of melanoma, squamous cell carcinoma, or basal cell carcinoma compared with the general population, with a mean follow-up of 7.3 years. The BAD/BPG 2022 guidelines note that NB-UVB carries a relatively low risk of side effects, including skin cancer risk, and recommend it specifically on those grounds.
As with any UV exposure, the picture changes at very high cumulative doses over many years — which is why treatment should always follow a clinically appropriate protocol, and why patients with a personal history of skin cancer are not suitable candidates. This is not a reason to avoid phototherapy. It is a reason to use it correctly.
Common side effects
The most frequently reported side effect during a course of NB-UVB phototherapy is erythema — redness of the skin — which occurs when a dose is slightly too high for that session. Mild, transient redness is a normal part of dose calibration and typically resolves within a day or two. Persistent or symptomatic erythema is less common but can occur, particularly when dosing is not carefully controlled. The LITE Trial recorded episodes of persistent erythema in 5.9% of home-based treatments — a rate that underscores why precise, dose-based treatment matters. Other common effects during a course of treatment include temporary dryness or itching of the skin. Eye protection — UV-blocking goggles — should always be worn during sessions, as the eyes are sensitive to UVB exposure.
Always consult your dermatologist first
Home phototherapy is a medical treatment, not a consumer product. Before starting any course, a consultation with a dermatologist is essential — to confirm suitability, rule out contraindications, and establish the correct starting dose and protocol for your skin type and condition. This is not a formality. It is the foundation of treatment that is both safe and effective.
The limitations of conventional home devices — and why they matter
Peer-reviewed research on home phototherapy identifies two limitations that are worth understanding before choosing a device. The first is a higher rate of adverse effects in home settings compared with clinical settings — a finding attributed primarily to the risk of device misuse or overuse when patients are self-administering without adequate guidance. The second is the tendency of conventional home phototherapy devices to experience a decrease in irradiance output over time— meaning that as the lamp degrades, a timer-based device delivers a progressively lower and less predictable dose. The patient has no way of knowing this is happening. The same time setting that was correct at the start of treatment may be delivering significantly less UV energy months later — leading to under-treatment, or conversely, to overdosing when a patient compensates by extending session time.
These limitations are not inherent to home phototherapy as a concept. They are specific to how most conventional devices are built — and they are solvable. A device that measures actual UV dose in real time rather than running on a timer removes the degradation problem entirely. A companion app that guides the patient through the correct protocol at every session removes the misuse risk. When both are present in a single certified medical device, the gap between home treatment and clinic treatment closes considerably. That is precisely the standard worth looking for.

Why Choose UV Tactus Over Other Devices?

When home phototherapy devices first came to market, most of them took one thing from the clinic: the lamp. A UV bulb in a handheld case, paired with a timer and a manual. Everything else that makes clinic treatment clinical — the dosimetry, the structured guidelines on how to perform treatment correctly and safely — was not included. Patients were handed a light source and largely left to work it out.
UV Tactus starts from the opposite direction. The question is not "how do we make a home device?" It is "how do we deliver exactly the same treatment a patient receives in a dermatology clinic — the same clinical standard, the same precision, the same controlled dosing — in a form that a patient can use independently at home, without any compromise?" Every technical decision follows from that single goal. And in doing so, UV Tactus directly addresses each of the limitations that peer-reviewed research has identified in conventional home phototherapy devices — lamp degradation, inaccurate dosing, and the risk of patients not knowing how to use their device correctly. These are not gaps patched after the fact. They are the problems UV Tactus exists to solve. The result is real clinical treatment at home — not an approximation of it.
That is why UV Tactus is the world's first portable, CE MDR-certified LED-powered narrowband UVB phototherapy device with an integrated professional dosimeter and a companion app for home use — a complete clinical system, certified by TUV Rheinland in Germany and listed with the MHRA in the UK. No other home phototherapy device brings this combination together.
Dose-based, not timer-based — addressing the dosing problem
In a dermatology clinic, treatment dose is measured by a professional dosimeter in mJ/cm² — actual UV energy delivered to the skin. A dosimeter tells you exactly how much therapeutic energy your skin received, and that is the clinical standard that matters.
Most home phototherapy devices use fluorescent lamps and a timer — but not a professional dosimeter. As the lamp degrades over months of use, the same time setting delivers progressively less UV energy — and the patient has no way of knowing this is happening. The dose that was correct at the start of treatment becomes unreliable over time, creating a real risk of both under-treatment and inadvertent overdosing when a patient extends session time to compensate.
UV Tactus uses an integrated professional dosimeter that measures actual UV energy delivered to the skin in real time, in mJ/cm² — identical to the standard used in dermatology clinics. It stops automatically when the correct prescribed dose is reached. Every session delivers precisely what it should, regardless of how long the device has been in use. The dosing problem is eliminated entirely.
LED technology — addressing the degradation problem
Fluorescent UV lamps degrade. Their output decreases over time, their light distribution is uneven, and they generate heat. This degradation is not just inconvenient — it is the root cause of the dosing unreliability that makes timer-based home devices clinically unpredictable over time.
UV Tactus uses 16 strategically placed LEDs — a technology chosen specifically because it maintains consistent output across thousands of treatments, distributes light evenly across the entire 106 cm² treatment surface, and generates no skin-heating effect. The treatment surface is divided into four individually controlled zones, each of which can be adjusted to direct light precisely where it is needed whilst shielding surrounding healthy skin.
Approximately twice the size of many competing devices, and rated for a lifetime of use — the degradation problem does not apply.
The companion app — because the device alone is not enough
Having the right device is only part of what makes treatment work. In a clinic, a patient does not simply stand in front of a lamp. They follow a medically supervised protocol — a structured sequence of sessions with correct dosing, correct intervals, and trained guidance at every step. Research has consistently identified the absence of this structure as the primary reason home phototherapy produces higher rates of adverse effects: patients who do not know the correct protocol, or who lose track of it over time, are the ones who run into difficulty.
This is what the UV Tactus companion app addresses. It is a personal clinical assistant that ensures every session is performed correctly, from the very first treatment. It calculates and suggests the correct dose for each body area and session, guides the patient through the correct protocol step by step, sends session reminders to maintain consistency, tracks progress across a built-in treatment calendar, and allows patients to share progress reports directly with their dermatologist. The device operates fully independently — the app does not control it — but together they give the patient everything they need to treat safely, consistently, and effectively. Not just the means to deliver light, but the knowledge and structure to use it correctly. Correct use and consistent adherence are what turn a good device into effective treatment — and the app ensures both, by eliminating confusion, keeping the patient on track, and making every session as safe and efficient as it can be. The result is not just fewer errors. It is better outcomes and greater confidence throughout the entire course of treatment.
Developed by a doctor who lives with psoriasis
UV Tactus is co-founded by Arunas Zebrauskas, a medical doctor who has psoriasis himself. The device is not designed in the abstract — it solves a real problem that its co-creator lives with every day. That clinical and personal authority runs through everything: how the device works, how support is structured, and how the company communicates with patients before purchase, during onboarding, and throughout treatment.
Every purchase includes free video onboarding sessions, comprehensive instructions for use, and active post-purchase support. A free pre-purchase consultation is available, with an expert responding within 24 hours.

92% of UV Tactus users report visible improvement within a few weeks of consistent use — based on over 123,000 phototherapy treatments performed with the device.

The Evidence Is Clear. The Question Is What You Do With It.

Home phototherapy is not a new idea that is still finding its feet. It is a clinically validated, guideline-endorsed treatment modality with a substantial and growing evidence base — and the conversation around it is shifting. Researchers and clinicians are increasingly calling for home NB-UVB to be considered a first-line treatment option, not a fallback for patients who cannot access a clinic. The LITE Trial investigators said exactly that. The direction of travel is clear.
The limitations that once gave clinicians pause — lamp degradation, inaccurate dosing, patients not knowing how to use their device correctly — were real concerns. But they were concerns about the technology available at the time, not about phototherapy itself. New device design, professional dosimetry, and structured digital guidance have answered those objections directly. LED technology eliminates the degradation problem entirely — maintaining consistent output across thousands of treatments, making the device a genuine long-term investment rather than a consumable. A professional dosimeter ensures every session delivers the correct dose in real time. And a companion app guides the patient through every session with the same rigour as a clinical setting. Together, they close the gap between home and clinic treatment. Not approximately. Actually.
That is where UV Tactus stands — a device and app built precisely to that standard, so that patients living with psoriasis, eczema, vitiligo, or another photoresponsive skin condition can access real clinical treatment on their own terms.

Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any phototherapy treatment.